Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina 27599-7305, USA.
Biol Blood Marrow Transplant. 2012 Apr;18(4):497-504. doi: 10.1016/j.bbmt.2011.10.014. Epub 2011 Oct 19.
With the advent of reduced-intensity conditioning regimens and improvements in supportive care, hematopoietic cell transplantation (HCT) has become increasingly available to older adults and medically vulnerable populations with hematologic diseases. However, adverse outcomes including long-term treatment-related distress, disability (frailty), and death remain important concerns in this population. In other areas of oncology, comprehensive geriatric assessments have been used to stratify patients for treatment-related risk, and patient-reported outcomes (PROs) have helped in understanding treatment-related toxicity from a patient perspective. However, these powerful tools have not yet become widely used in HCT. Here, we review the theories and available data that support the development of pretreatment functional assessments and longitudinal PRO sampling in HCT. We discuss the potential for these techniques to improve transplantation outcomes through risk stratification, interventional studies, and predictive models that incorporate genetic and biomarker data. Predicting and understanding long-term transplantation-related toxicity through functional assessments and PROs will be critical to calculating the risk/benefit ratio of aggressive therapies in older patient populations, and we contend that functional assessments and PRO sampling should become standard parts of the routine evaluation of HCT patients.
随着减强度预处理方案的出现和支持性治疗的改善,造血细胞移植(HCT)越来越多地应用于老年患者和有血液系统疾病的医学上脆弱人群。然而,在这些人群中,长期治疗相关的困扰、残疾(虚弱)和死亡等不良结局仍然是重要关注点。在肿瘤学的其他领域,全面老年评估已被用于对患者进行治疗相关风险分层,患者报告的结局(PROs)有助于从患者角度了解治疗相关毒性。然而,这些强大的工具尚未在 HCT 中广泛应用。在这里,我们回顾了支持在 HCT 中进行预处理功能评估和纵向 PRO 采样的理论和现有数据。我们讨论了这些技术通过风险分层、干预研究和纳入遗传和生物标志物数据的预测模型来改善移植结局的潜力。通过功能评估和 PRO 预测和了解长期移植相关毒性,对于计算老年患者群体中强化治疗的风险/获益比至关重要,我们认为功能评估和 PRO 采样应成为 HCT 患者常规评估的标准部分。